Company / R&D Expense
Harmony Biosciences Holdings, Inc. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$189.6M
FY2025
5-year range
$69.6M / $189.6M
FY2021-FY2025
Trend
+30.0%
vs FY2024
Sector context
#84 of 210
Health Care
What the data says
At $190M, Harmony Biosciences Holdings, Inc.'s r&d expense ranks #84 of 210 in the Health Care sector. R&D Expense has increased for 4 consecutive years, from $70M in FY2021 to $190M in FY2025.
Based on SEC 10-K filings.
$190M in FY2025 with a 5-year CAGR of +22.2%.
Improved from $76M to $190M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +38.8%
- 5-Year CAGR
- +22.2%
- 10-Year CAGR
- -
Sector benchmark
#84 of 210 in Health CareTop 40% of 210This company $189.6M Sector average $644.0M
▼
-70.6% below sector average
Key checks
Key Insights
- Harmony Biosciences Holdings, Inc.'s r&d expense has grown for 4 consecutive years.
- 5-year CAGR of +22.2%, indicating consistent growth.
- In FY2025, r&d expense increased 30.0% year-over-year.
- Ranks #84 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $189.6M | +30.0% |
| FY2024 | $145.8M | +91.7% |
| FY2023 | $76.1M | +7.3% |
| FY2022 | $70.9M | +1.9% |
| FY2021 | $69.6M | +0.0% |
| FY2020 | $69.6M | +0.0% |
| FY2019 | $69.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026